Nevertheless, these mechanistic, mouse, and human ccRCC studies support a working hypothesis in which the disarmed “STAT-PD-1” immunosurveillance CB can be reactivated through biological means such as anti-PD-1/L1 antibodies for therapeutic exploitation (Fig. 1D). This evidence concerns the gene SOAT1 and nonpapillary renal cell carcinoma.